付林，男，医学博士，教授，主任医师，博士生导师，广州医科大学第三层次引进人才，“南山学者”特聘教授，广州医科大学附属第二医院血液科主任。付林教授于南开大学获得博士学位后进入北京大学医学部进行临床和科研工作，获批助理教授（tenure track），后被引进至广州医科大学进行临床、科研和教学工作。付林教授的研究领域为血液肿瘤的基础和临床，聚焦于急性髓系白血病的发病机制及靶向治疗。近3年，在急性髓系白血病研究领域，付林教授以通讯作者（限排名最后），第一作者（限排名第一）在血液学，肿瘤学，骨髓移植等领域知名杂志发表发表SCI论文46篇，最高影响因子17.885，累计影响因子超过200分。
电子邮箱：fulin022@126.com
办公地址：广州医科大学附属二院门诊楼1203
研究方向与特色
研究领域为血液肿瘤的基础和临床，聚焦于急性髓系白血病的遗传学及表观遗传学发病机制和靶向治疗。特色研究方向为：
[1] 探究正常核型AML（CN-AML）分层预后靶标，以期细化临床CN-AML的危险度分层；
[2] 探究异基因造血干细胞移植AML患者的危险度分层指标，以期提高移植后患者生存；
[3] 在t(8;21)AML中深入探究疾病的发展机制，以期为AML患者诊断治疗提供可靠的科学依据；
[4] 生物信息学与医学临床基础相结合，利用临床大数据分析构建临床大数据管理框架。
主持研究项目
[1] 国家自然科学联合基金项目，U1903117，DNA甲基化/microRNA-195和RUNX1调控环路/NF-κB促进正常核型急性髓系白血病的进展，2020.01-2022.12，57.00万，在研，主持。
[2] 广州医科大学“南山学者优秀人才”科研启动经费，B195002014027，急性髓系白血病的基础和临床研究，2018.12-2023.12，500.00万，在研，主持。
[3] 国家自然科学青年基金，81500118，MAP7在正常核型急性髓系白血病中的预后意义及分子机制，2016.01-2018.12，21.50万，结题，主持。
人才称号及社会兼职
[1] 2019年、2020年广东省岭南名医
[2] 2019年广州市高层次医学重点人才
[3] 广东省青年后备人才
[4] 《血栓与止血学》杂志副主编
[5] 中国研究型医院学会血液病精准诊疗专业委员会委员，2015
[6] 江苏省医学会血液学分会青年委员会委员，2016
[7] 中国医药教育血液专业委员会青委会常委
研究生培养
[1] 在站博士后4名。
[2] 在读博士研究生2名。
[3] 在读硕士研究生7名。
研究论文（第一和通讯作者论文，*代表通讯作者）
2021
[1] Zeng T#, Cui L#, Huang W#, Liu Y, Si C, Qian T, Deng C, Fu L*. The establishment of a prognostic scoring model based on the new tumor immune microenvironment classification in acute myeloid leukemia. BMC Med. 2021. Doi: 10.1186/s12916-021-02047-9. (IF: 8.775)
[2] Cheng Z#, Dai Y#, Huang W, Zhong Q, Zhu P, Zhang W, Wu Z, Lin Q, Zhu H, Cui L, Qian T, Deng C, Fu L*, Liu Y*, Zeng T*. Prognostic Value of MicroRNA-20b in Acute Myeloid Leukemia. Front Oncol. 2021 Feb 18;10:553344. (IF：6.244)
[3] Dai Y#, Cheng Z#, Fricke D R, Zhao H, Huang W, Zhong Q, Zhu P, Zhang W, Wu Z, Lin Q, Zhu H, Liu Y, Qian T, Fu L*, Cui L*, Zeng T*. 2021. Prognostic role of Wnt and Fzd gene families in acute myeloid leukaemia.Journal of Cellular and Molecular Medicine, 25(3): 1456-1467. (IF:5.531)
[4] Huang W#, Qian T#, Huang Z, Liu Y, Cui L, Zhu P, Zhong Q, Zeng T, Fu L*, Si C*, Deng C*. 2021. Increased expression of IFI16 predicts adverse prognosis in multiple myeloma. The Pharmacogenomics Journal, 21(4): 520-532. (IF:3.633)
[5] Zhu P#, Qian T#, Si C#, Liu Y, Cui L, Huang W, Fu L*, Deng C*, Zeng T*. 2021. High expression of CPNE5 and CPNE9 predicts positive prognosis in multiple myeloma. Cancer Biomarkers, 31(1): 77-85. (IF:4.388)
2020
[6] Yang RY, Yang CX, Lang XP, Duan LJ, Wang RJ, Zhou W, Wu GS, Li Y, Qian T*, Xiao S*, Fu L*. Identification of a novel RUNX1-TACC1 fusion transcript in acute myeloid leukaemia. Br J Haematol. 2020 Apr;189(2):e52-e56.(IF：6.998)
[7] Quan L#, Qian T, Cui L, Liu Y,Fu L*, Si C. Prognostic role of minichromosome maintenance family in multiple myeloma. Cancer Gene Ther.2020,27(10-11):819-829:819-829doi:10.1038/s41417-020-0162-2. (IF: 5.987)
[8] Cui L#, Liu Y, Pang Y, Qian T, Quan L, Cheng Z, Dai Y, Ye X, Pang Y, Shi J, Ke X, Wu D, Fu L*. Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia. Cancer Gene Ther.2020,27(1-2):1-14. doi:10.1038/s41417-019-0119-5. (IF: 5.987)
[9] Dai Y#, Cheng Z#, Pang Y, Jiao Y, Qian T, Quan L, Cui L, Liu Y, Si C, Chen J, Ye X, Chen J, Shi J, Wu D, Zhang X, Fu L*. Prognostic value of the FUT family in acute myeloid leukemia. Cancer Gene Ther. 2020,27(1-2):70-80.doi:10.1038/s41417-019-0115-9. (IF:5.987)
[10] Liu Y#, Lu R, Cui W, Pang Y, Liu C, Cui L, Qian T, Quan L, Dai Y, Jiao Y, Pan Y, Ye X, Shi J, Cheng Z, Fu L*. 2020. High IFITM3 expression predicts adverse prognosis in acute myeloid leukemia. Cancer Gene Ther.2020,27(1-2):38-44.doi:10.1038/s41417-019-0093-y. (IF:5.987)
[11] Quan L#, Cheng Z#, Dai Y, Jiao Y, Shi J, Fu L*. 2020. Prognostic significance of PAK family kinases in acute myeloid leukemia. Cancer Gene Ther.2020,27(1-2):30-37 doi:10.1038/s41417-019-0090-1. (IF:5.987)
[12] Cui L#, Cheng Z#, Liu Y, Dai Y, Pang Y, Jiao Y, Ke X, Cui W, Zhang Q, Shi J, Fu L*. Overexpression of PDK2 and PDK3 reflects poor prognosis in acute myeloid leukemia. Cancer Gene Ther. 2020 Feb;27(1-2):15-21. (IF：5.987)
[13] Cheng Z#, Dai Y#, Zeng T, Liu Y, Cui L, Qian T, Si C, Huang W, Pang Y, Ye X, Shi J, Fu L*. 2020. Upregulation of Glutamic-Oxaloacetic Transaminase 1 Predicts Poor Prognosis in Acute Myeloid Leukemia. Front Oncol.2020,10:379. doi:10.3389/fonc.2020.00379.(IF:6.244)
[14] Fu L#, Cheng Z, Dong F, Quan L, Cui L, Liu Y, Zeng T, Huang W, Chen J, Pang Y, Ye X, Wu G, Qian T, Chen Y, Si C. 2020. Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma. J Cancer.2020,11(5):1182-1194.doi:10.7150/jca.37313. (IF:4.207)
[15] Huang W#, Qian T#, Cheng Z, Zeng T, Si C, Liu C, Deng C, Ye X, Liu Y, Cui L, Fu L*. 2020. Prognostic significance of Spinster homolog gene family in acute myeloid leukemia. J Cancer.2020,11(15):4581-4588. doi:10.7150/jca.44766. (IF:4.207)
[16] Cheng Z#, Dai Y#, Pang Y, Jiao Y, Liu Y, Cui L, Quan L, Qian T, Zeng T, Si C, Huang W, Chen J, Pang Y, Ye X, Shi J, Fu L*. Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia. J Cell Mol Med. 24(1): 1067-1075doi:10.1111/jcmm.14831. (IF:5.310)
[17] Qian T#, Cui L, Liu Y, Cheng Z, Quan L, Zeng T, Huang W, Dai Y, Chen J, Liu L, Chen J, Pang Y, Wu G, Ye X, Shi J, Fu L*, Si C. 2020. High expression of chaperonin-containing TCP1 subunit 3 may induce dismal prognosis in multiple myeloma. Pharmacogenomics J, 20(4): 563-573.doi:10.1038/s41397-019-0145-6. (IF:3.633)
[18] Qian T#, Cheng Z#, Quan L, Zeng T, Cui L, Liu Y, Si C, Huang W, Dai Y, Chen J, Liu L, Jiao Y, Deng C, Pang Y, Ye X, Shi J, Fu L*. 2020. Prognostic role of SCAMP family in acute myeloid leukemia. Pharmacogenomics J.20(4): 595-600. doi:10.1038/s41397-020-0149-2. (IF:3.633)
2019
[19] Liu Y, Cheng Z, Pang Y, Cui L, Qian T, Quan L, Zhao H, Shi J, Ke X, Fu L*. Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia. J Hematol Oncol. 2019 May 24;12(1):51. (IF:17.388)
[20] Zhang J, Zhang L, Cui H, Zhang X, Zhang G, Yang X, Yang S, Zhang Z, Wang J, Hu K, Shi J, Ke X,Fu L*. High expression levels of SMAD3 and SMAD7 at diagnosis predict poor prognosis in acute myeloid leukemia patients undergoing chemotherapy. Cancer Gene Ther. 2019: 26:119–127. (5.987)
[21] Liu Y, Cheng Z, Li Q, Pang Y, Cui L, Qian T, Quan L, Dai Y, Jiao Y, Zhang Z, Ye X, Shi J, Fu L*. Prognostic significance of the PANK family expression in acute myeloid leukemia. Ann Transl Med. 2019;7(12):261. (IF: 3.932)
[22] Cheng, Zhiheng; Dai, Yifeng; Pang, Yifan; Jiao, Yang; Zhao, Hongmian; Zhang, Zhihui; Qin, Tong; Hu, Ning; Zhang, Yijie; Ke, Xiaoyan; Chen, Yang; Wu, Depei; Shi, Jinlong; Fu, Lin * Enhanced expressions of FHL2 and iASPP predict poor prognosis in acute myeloid leukemia. Cancer Gene Ther. 2019; 26(1-2):17-25. (IF: 5.987)
[23] Zhang G, Zhang J, Yang X, Zhang X, Yang S, Wang J, Hu K, Shi J, Ke X*,Fu L*. High expression of dedicator of cytokinesis 1 adversely influences the prognosis of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Cancer Management and Research. 2019; 11: 3053-3060. doi: 10.2147/cmar.S192845. (IF:3.989)
[24] Cheng Z, Dai Y, Pang Y, Jiao Y, Liu Y, Cui L, Qian T, Quan L, Cui W, Pan Y, Ye X, Jinlong Shi*, Fu L*. High EGFL7 expression may predict poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Cancer Biology & Therapy, 2019; 20:10, 1314-1318. (IF: 4.742)
[25] Hu N, Cheng Z, Pang Y, Zhao H, Ding H, Chen L, Li Q, Han Y, Qin T, Dai Y, Zhang Y, Shi J, Wu D, Fu L*. Prognostic effect of allogeneic hematopoietic stem cell transplantation on first and non-first complete remission in acute myeloid leukemia. Ann Transl Med. 2019; 7(18):500. (IF: 3.932)
[26] Cui L, Cheng Z, Hu K, Pang Y, Liu Y, Qian T, Quan L, Dai Y, PangY, Ye X, Shi J, Fu L*. Prognostic value of the PDLIM family in acute myeloid leukemia. Am J Transl Res2019;11(9):6124-6131. (IF: 4.060)
[27] Hu N, Pang Y, Zhao H, Si C, Ding H, Chen L, Wang C, Qin C, LiQ, Han Y, Dai Y, ZhangY, Shi J, Wu D, Zhang Y*, Cheng Z*, Fu L*. High expression of DOCK2 indicates good prognosis in acute myeloid leukemia. Journal of Cancer 2019; 10(24): 6088-6094. (IF: 4.207)
[28] Yang X, Shi J, Zhang X, Zhang G, Zhang J, Yang S, Wang J, Ke X*, Fu L*. Expression level of GAS6-mRNA influences the prognosis of acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation.Biosci Rep. 2019;39(5). (IF: 3.840)
[29] Hu N, Cheng Z, Pang Y, Zhao H, Chen L, Wang C, Qin T, Li Q, Han Y, Shi J*, Fu L*. High expression of MiR-98 is a good prognostic factor in acute myeloid leukemia patients treated with chemotherapy alone. J Cancer. 2019 10: 178-185. doi: 10.7150/jca.26391. (IF:4.207)
[30] Zhang G, Zhang L, Yang X, Zhang X, Zhang J, Yang S, Wang J, Hu K, Shi J, Ke X,Fu L*. High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2019 Feb; 98: 519-525. doi: 10.1007/s00277-018-3440-4. (IF:3.673)
[31] Zhang J, Shi J, Zhang G, Zhang X, Yang X, Yang S, Wang J, Hu K, Ke X, Fu L*. MicroRNA-425 upregulation indicates better prognosis in younger acute myeloid leukemia patients undergoing chemotherapy. Oncol Lett. 2019;17(6):5793-5802. (IF: 2.967)
[32] Zhang G, Shi J, Wang J, Ke X, Fu L*. High expression of microRNA-500 is associated with poor prognosis in acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation. Oncol Lett. 2019; 17(6):5815-5820. (IF: 2.967)
[33] Hu K, Gao JJ, Li QH, Tian L, Wan W, Zhao W, Wang JJ*, Fu L*. Autologous hematopoietic stem cell transplantation as first-line consolidation therapy can improve the prognosis of diffuse large B-cell lymphoma with high expression of MYC protein. Kaohsiung J Med Sci.2019;35(7):425-431. (IF: 2.744)
2018
[34] Zhou L#, Fu L#, Lv N, Liu J, Li Y, Chen X, Xu Q, Chen G, Pang B, Wang L, Li Y, Zhang X, Yu L*. Methylation-associated silencing of BASP1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia. Exp Mol Med. 2018 Apr 20; 50: 44. doi: 10.1038/s12276-018-0067-4. (IF:8.718)
[35] Cheng Z, Dai Y, Pang Y, Jiao Y, Zhao H, Wu S, Zhang L, Zhang Y, Wang X, Wang L, Ma D, Qin T, Hu N, Zhang Y, Hu K, Zhang Q, Shi J,Fu L*. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1. Cell PhysiolBiochem. 2018; 47: 1853-1861. doi: 10.1159/000491065. (IF:5.500)
[36] Cheng Z#, Zhou L#, Hu K#, Dai Y#, Pang Y, Zhao H, Wu S, Qin T, Han Y, Hu N, Chen L, Wang C, Zhang Y, Wu D, Ke X, Shi J*, Fu L*. Prognostic significance of microRNA-99a in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018 Sep; 53: 1089-1095. doi: 10.1038/s41409-018-0146-0, (IF:5.483)
[37] Cheng Z, Dai Y, Pang Y, Jiao Y, Zhao H, Zhang Z, Qin T, Hu N, Zhang Y, Ke X, Chen Y*, Wu D*, Shi J*, Fu L*. Enhanced expressions of FHL2 and iASPP predict poor prognosis in acute myeloid leukemia. Cancer Gene Ther. 2018; 26: 17-25. doi: 10.1038/s41417-018-0027-0. (IF:5.987)
[38] Cheng Z#, Hu K#, Tian L#, Dai Y#, Pang Y, Cui W, Zhao H, Qin T, Han Y, Hu N, Chen L, Wang C, Zhang Y, Wu D, Ke X, Shi J*, Fu L*. Clinical and biological implications of mutational spectrum in acute myeloid leukemia of FAB subtypes M4 and M5. Cancer Gene Ther. 2018 May; 25: 77-83. doi: 10.1038/s41417-018-0013-6. (IF:5.987)\
[39] Wu QY#, Ma MM#, Fu L#, Zhu YY, Liu Y, Cao J, Zhou P, Li ZY, Zeng LY, Li F*, Wang XY*, Xu KL*. Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms. Int J Biol Macromol. 2018 Sep; 116: 1064-1073. doi: 10.1016/j.ijbiomac.2018.05.120. (IF:6.953)
[40] Yang X, Shi J, Zhang X, Zhang G, Zhang J, Yang S, Wang J, Ke X, Fu L*. Biological and clinical influences of NPM1 in acute myeloid leukemia patients with DNMT3Amutations. Cancer Manag Res. 2018; 10: 2489-2497. doi: 10.2147/cmar.S166714
[41] Zhang X, Shi J, Zhang J, Yang X, Zhang G, Yang S, Wang J, Ke X, Fu L*. Clinical and biological implications of IDH1/2 in acute myeloid leukemia with DNMT3Amut. Cancer Manag Res, 2018 10: 2457-2466. doi: 10.2147/CMAR.S157632
[42] Zhang Q#, Fu L#, Liang Y, Guo Z, Wang L, Ma C, Wang H. Exosomes originating from MSCs stimulated with TGF-beta and IFN-gamma promote Treg differentiation. J Cell Physiol. 2018 Sep; 233: 6832-6840. doi: 10.1002/jcp.26436. (IF:6.384)
[43] Cheng Z, Dai Y, Wang J, Shi J*, Ke X*, Fu L*. High PD-L1 expression predicts poor prognosis in diffuse large B-cell lymphoma. Ann Hematol. 2018 Jun; 97: 1085-1088. doi: 10.1007/s00277-018-3266-0. (IF:3.673)
[44] Zhang J, Shi J, Zhang G, Zhang X, Yang X, Yang S, Wang J, Ke X, Fu L*. BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2018 Aug; 97: 1391-1397. doi: 10.1007/s00277-018-3331-8. (IF:3.673)
2017
[45] Qin T, Wu S, Zhao H, Xu K, Fu H, Cheng Z, Pang Y, Han Y, Chen L, Wang C, Zhang Y, Ke X, Xu K, Shi J, Fu L*. Molecular predictors of post-transplant survival in acute myeloid leukemia. Blood Cancer Journal. 2017; 7. doi: 10.1038/s41408-017-0027-6. (IF：11.037)
[46] Fu L#, Shi J, Liu A, Zhou L, Jiang M, Fu H, Xu K, Li D, Deng A, Zhang Q, Pang Y, Guo Y, Hu K, Zhou J, Wang Y, Huang W, Jing Y, Dou L, Wang L, Xu K, Ke X, Nervi C, Li Y*, Yu L*. A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia. Int J Cancer. 2017 Feb 1; 140: 653-661. doi: 10.1002/ijc.30481. (IF:7.396)
[47] Fu L#, Fu H#, Qiao J#, Pang Y, Xu K, Zhou L, Wu Q, Li Z, Ke X*, Xu K*, Shi J*. High expression of CPNE3 predicts adverse prognosis in acute myeloid leukemia. Cancer Sci. 2017 Sep; 108: 1850-1857. doi: 10.1111/cas.13311. (IF:6.716)
[48] Fu L#, Fu H#, Wu Q#, Pang Y, Xu K, Zhou L, Qiao J, Ke X*, Xu K*, Shi J*. High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions. J Transl Med. 2017 Jul 19; 15: 159. doi: 10.1186/s12967-017-1260-2. (IF:5.531)
[49] Zhou L#, Fu L#, Lv N#, Chen X, Liu J, Li Y, Xu Q, Huang S, Zhang X, Dou L, Wang L, Li Y, Yu L*. A minicircuitry comprised of microRNA-9 and SIRT1 contributes to leukemogenesis in t (8; 21) acute myeloid leukemia. Eur Rev Med Pharmacol Sci. 2017; 21(4): 786-794. (IF:3.507)
2016
[50] Shi J#, Fu H#, Jia Z, He K, Fu L*, Wang W*. High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia. EBioMedicine. 2016 Dec; 14: 55-64. doi: 10.1016/j.ebiom.2016.11.025. (IF:8.1453)
[51] Fu L#, Fu H#, Zhou L#, Xu K, Pang Y, Hu K, Wang J, Tian L, Liu Y, Wang J, Jing H, Huang W*, Ke X*, Shi J*. High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia. Sci Rep. 2016 Sep 30; 6: 34546. doi: 10.1038/srep34546. (IF:4.379)
[52] Fu L#, Shi J#, Liu J, Liu A, Xu K, Ke X*. Combining retinoic acid and oral arsenic may be potentially the first-line therapy for non-high-risk acute promyelocytic leukemia. Stem Cell Investig. 2016 3: 93. doi: 10.21037/sci.2016.11.13
[53] Fu L#, Fu H#, Tian L#, Xu K, Hu K, Wang J, Wang J, Jing H, Shi J*, Ke X*. High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia[J]. Oncotarget. 2016; 7(13): 15828.
2015
[54] Shi J#, Lin F#, Li Y, Li Y*,Wang W*. Identification of let-7a-2-3p or/and miR-188-5p as Prognostic Biomarkers in Cytogenetically Normal Acute Myeloid Leukemia. Plos One. 2015 10. doi: 10.1371/journal.pone.0118099. (IF:3.240)
[55] Shi J#, Fu L#, Ang Q, Wang G, Zhu J, Wang W*. Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia. Oncotarget. 2016; 7(3): 2585.
[56] Fu L#, Shi J#, Hu K, Wang J, Wang W*, Ke X*. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia. Oncotarget. 2015; 6(10): 8144.
[57] Shi J#, Fu L#,, Wang W*. High expression of inositol 1, 4, 5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia[J]. Oncotarget. 2015; 6(7): 5299.
2014
[58] Fu L#, Huang W, Jing Y, Jiang M, Zhao Y, Shi J, Huang S, Xue X, Zhang Q, Tang J, Dou L, Wang L, Nervi C, Li Y*, Yu L*. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia. FEBS J. 2014 Feb; 281: 1123-1131. doi: 10.1111/febs.12673. (IF:5.542)
